5 Key Takeaways

• 1

  Researchers identified the molecular trigger for rare clotting linked to adenoviral COVID-19 vaccines, targeting platelet factor 4 (PF4).

• 2

  The study addresses vaccine-induced immune thrombocytopenia and thrombosis (VITT), a syndrome first noted in 2021 after adenoviral vector vaccine rollout.

• 3

  Adenoviral core protein VII (pVII) was identified as the likely antigen inciting the immune response that mistakenly targets PF4.

• 4

  Nearly all patients with VITT shared a specific immunoglobulin light-chain variant and a somatic mutation known as K31E.

• 5

  Modifying or removing pVII in future vaccines could prevent this rare reaction while maintaining strong disease protection.